Evidence map›Paper›PMID 32685436›Full record

ReviewERJ open research2020

D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review.

Sofia Vidali, Daniele Morosetti, Elsa Cossu, Maria Luisa Eliana Luisi, Silvia Pancani, Vittorio Semeraro, Guglielmo Consales

Open access · goldAbstract readReview
In one paragraph

Review in ERJ open research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Corticosteroid treatment for post-COVID-19 persistent interstitial lung disease: a randomized clinical trial.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Evaluation of COVID-19 cases treated in the intensive care unit in a coastal city hospital during the pandemic.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Article
  13. Article
  14. Article
  15. Advances in Biomarkers for Diagnosis and Treatment of ARDS.Diagnostics (Basel, Switzerland) · 2023
    Review
  16. Study of Biochemical Parameters as Predictors for Need of Invasive Ventilation in Severely Ill COVID-19 Patients.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2023
    Article
  17. Article
  18. Review
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sofia VidaliDiagnostic and Interventional Imaging, University Hospital Policlinico Tor Vergata, Rome, Italy.ORCID https://orcid.org/0000-0001-5982-4387
Daniele MorosettiDiagnostic and Interventional Imaging, University Hospital Policlinico Tor Vergata, Rome, Italy.ORCID https://orcid.org/0000-0001-9234-3972
Elsa CossuDiagnostic and Interventional Imaging, University Hospital Policlinico Tor Vergata, Rome, Italy.
Maria Luisa Eliana LuisiMetabolism and Nutrition Unit, IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.
Silvia PancaniWitheca, Witapp srl, Florence, Italy.
Vittorio SemeraroDiagnostic and Interventional Imaging, Santissima Annunziata Hospital, Taranto, Italy.
Guglielmo ConsalesAnesthesiology and Resuscitation, Santo Stefano Hospital, Prato, Italy.
Policlinico Tor Vergata · ITAzienda Usl Toscana Centro · ITDon Carlo Gnocchi Foundation · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) stimulates pro-thrombotic changes. This, combined with its tropism for endothelium and lung structures, may explain its association with thrombotic events, reduction of pulmonary gas exchange, acute respiratory distress syndrome (ARDS) and a composite end-point (intensive care unit, invasive ventilation, death). This study aims to highlight the correlation between elevated D-dimer (an indirect thrombosis marker) and the increased rate of poor prognosis-associated conditions, and to introduce D-dimer-labelled anticoagulant administration as a potentially useful tool to prevent complications and positively influence coronavirus disease 2019 (COVID-19) course.

methodsAn online database search (PubMed, Google Scholar, Scopus, Web of Science and Cochrane) was performed between 13 March and 10 April 2020. The most relevant keywords were "D-dimer", "SARS-CoV-2", "COVID-19", "thrombosis" and "ARDS". Selection was independently conducted by three reviewers. References and previews of accepted articles were evaluated. Data inclusion/extraction inaccuracy was limited by the work of three reviewers. Selection bias reduction was addressed by thoughtfully designing the search protocol. Quality assessment was performed with the Newcastle-Ottawa Scale. The systematic review protocol was not registered because we anticipated the very limited available evidence on the topic and due to the urgency of the study.

results16 studies were evaluated. Good-quality criteria were reached in 13 out of 16 studies. D-dimer was increased and significantly higher in COVID-19 patients compared with healthy controls, in COVID-19 patients with severe disease or a composite end-point compared with non-severe disease, in ARDS compared with non-ARDS patients and in deceased ARDS patients compared with ARDS patients who survived (all p<0.001). COVID-19 patients treated with anticoagulants demonstrated lower mortality compared with those not treated (p=0.017).

conclusionsCorrelations exist between COVID-19 infection, severe elevation of D-dimer levels, and increase in the rate of complications and composite end-point. The appropriateness of early and continuous D-dimer monitoring and labelled anticoagulation as management tools for COVID-19 disease deserves accurate investigation, to prevent complications and reduce interventions.

Identifiers

PMID32685436
PMCPMC7357271
OpenAlexW3041300800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.